← Back to Clinical Trials
Recruiting NCT06555094

NCT06555094 Randomized Clinical Trial of Supplementing Brief Psychotherapy With a Mobile App

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06555094
Status Recruiting
Phase
Sponsor Rutgers, The State University of New Jersey
Condition Suicidal Ideation
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-05-14
Primary Completion 2024-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Ecological momentary assessment (EMA)Treatment as usual (TAU)Brief skills sessions plus EMI skills practice prompts

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2024-05-14 with a primary completion date of 2024-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to determine whether learning three skills for managing negative emotions and receiving reminders via smartphone to practice these skills reduces how often and how intensely one experiences emotional distress and suicidal thoughts.

Eligibility Criteria

Inclusion Criteria: * adult status (18+ years), * a recent suicide attempt or any report of current suicidal ideation, * the ability to speak and write English fluently, ownership of and consistent access to an internet-capable smartphone (e.g., an iPhone or Android phone), and Exclusion criteria: \- the presence of any factor that impairs an individual\'s ability to provide informed consent and comprehend and effectively participate in the study including: an inability to speak or write English fluently, the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior.

Contact & Investigator

Central Contact

Evan Kleiman, Ph.D.

✉ evan.kleiman@rutgers.edu

📞 1-848-445-2345

Principal Investigator

EVAN KLEIMAN, Ph.D.

PRINCIPAL INVESTIGATOR

Rutgers, The State University of New Jersey

Frequently Asked Questions

Who can join the NCT06555094 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Suicidal Ideation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06555094 currently recruiting?

Yes, NCT06555094 is actively recruiting participants. Contact the research team at evan.kleiman@rutgers.edu for enrollment information.

Where is the NCT06555094 trial being conducted?

This trial is being conducted at Piscataway, United States.

Who is sponsoring the NCT06555094 clinical trial?

NCT06555094 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is EVAN KLEIMAN, Ph.D. at Rutgers, The State University of New Jersey. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology